156 related articles for article (PubMed ID: 25192889)
1. Prognostic significance of microRNA expression in completely resected lung adenocarcinoma and the associated response to erlotinib.
Yan G; Yao R; Tang D; Qiu T; Shen Y; Jiao W; Ge N; Xuan Y; Wang Y
Med Oncol; 2014 Oct; 31(10):203. PubMed ID: 25192889
[TBL] [Abstract][Full Text] [Related]
2. Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status.
Pak MG; Lee CH; Lee WJ; Shin DH; Roh MS
Diagn Pathol; 2015 Jul; 10():99. PubMed ID: 26170125
[TBL] [Abstract][Full Text] [Related]
3. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
Kim MH; Kim HR; Cho BC; Bae MK; Kim EY; Lee CY; Lee JS; Kang DR; Kim JH
Lung Cancer; 2014 May; 84(2):196-202. PubMed ID: 24629638
[TBL] [Abstract][Full Text] [Related]
4. BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations.
Karachaliou N; Costa C; Gimenez-Capitan A; Molina-Vila MA; Bertran-Alamillo J; Mayo C; Massuti B; Majem M; Carcereny E; Moran T; Sanchez JJ; Viteri S; Gasco A; Wannesson L; Souglakos J; Jimeno J; Rosell R;
J Thorac Oncol; 2013 Mar; 8(3):295-300. PubMed ID: 23407556
[TBL] [Abstract][Full Text] [Related]
5. Biological characteristics and epidermal growth factor receptor tyrosine kinase inhibitors efficacy of EGFR mutation and its subtypes in lung adenocarcinoma.
Lu RL; Hu CP; Yang HP; Li YY; Gu QH; Wu L
Pathol Oncol Res; 2014 Apr; 20(2):445-51. PubMed ID: 24297623
[TBL] [Abstract][Full Text] [Related]
6. Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib.
Younes M; Wu Z; Dupouy S; Lupo AM; Mourra N; Takahashi T; Fléjou JF; Trédaniel J; Régnard JF; Damotte D; Alifano M; Forgez P
Oncotarget; 2014 Sep; 5(18):8252-69. PubMed ID: 25249545
[TBL] [Abstract][Full Text] [Related]
7. Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study.
Lee JH; Lee HY; Ahn MJ; Park K; Ahn JS; Sun JM; Lee KS
Cancer Imaging; 2016 Mar; 16():5. PubMed ID: 26984681
[TBL] [Abstract][Full Text] [Related]
8. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.
D'Angelo SP; Janjigian YY; Ahye N; Riely GJ; Chaft JE; Sima CS; Shen R; Zheng J; Dycoco J; Kris MG; Zakowski MF; Ladanyi M; Rusch V; Azzoli CG
J Thorac Oncol; 2012 Dec; 7(12):1815-1822. PubMed ID: 23154553
[TBL] [Abstract][Full Text] [Related]
9. Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
Urata Y; Katakami N; Morita S; Kaji R; Yoshioka H; Seto T; Satouchi M; Iwamoto Y; Kanehara M; Fujimoto D; Ikeda N; Murakami H; Daga H; Oguri T; Goto I; Imamura F; Sugawara S; Saka H; Nogami N; Negoro S; Nakagawa K; Nakanishi Y
J Clin Oncol; 2016 Sep; 34(27):3248-57. PubMed ID: 27022112
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study (MOTIVATE).
Sarosi V; Losonczy G; Francovszky E; Tolnay E; Torok S; Galffy G; Hegedus B; Dome B; Ostoros G
Lung Cancer; 2014 Oct; 86(1):54-8. PubMed ID: 25129367
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma.
Li N; Ou W; Yang H; Liu QW; Zhang SL; Wang BX; Wang SY
Cancer; 2014 May; 120(9):1379-86. PubMed ID: 24481719
[TBL] [Abstract][Full Text] [Related]
12. microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation.
Shen Y; Tang D; Yao R; Wang M; Wang Y; Yao Y; Li X; Zhang H
Med Oncol; 2013 Dec; 30(4):750. PubMed ID: 24198203
[TBL] [Abstract][Full Text] [Related]
13. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
[TBL] [Abstract][Full Text] [Related]
14. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
Yang CJ; Hung JY; Tsai MJ; Wu KL; Liu TC; Chou SH; Lee JY; Hsu JS; Huang MS; Chong IW
BMC Pharmacol Toxicol; 2017 May; 18(1):21. PubMed ID: 28486985
[TBL] [Abstract][Full Text] [Related]
15. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations.
Chiu CH; Yang CT; Shih JY; Huang MS; Su WC; Lai RS; Wang CC; Hsiao SH; Lin YC; Ho CL; Hsia TC; Wu MF; Lai CL; Lee KY; Lin CB; Yu-Wung Yeh D; Chuang CY; Chang FK; Tsai CM; Perng RP; Chih-Hsin Yang J
J Thorac Oncol; 2015 May; 10(5):793-799. PubMed ID: 25668120
[TBL] [Abstract][Full Text] [Related]
16. Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinib.
Takeda M; Okamoto I; Nakagawa K
J Thorac Oncol; 2014 Feb; 9(2):200-4. PubMed ID: 24419417
[TBL] [Abstract][Full Text] [Related]
17. Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.
Li J; Zhang L; Zhu H; Pan W; Zhang N; Li Y; Yang M
DNA Cell Biol; 2018 Nov; 37(11):903-908. PubMed ID: 30277797
[TBL] [Abstract][Full Text] [Related]
18. EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy.
Guo H; Wan Y; Tian G; Liu Q; Kang Y; Li Y; Yao Z; Lin D
Oncol Rep; 2012 Mar; 27(3):880-90. PubMed ID: 22134479
[TBL] [Abstract][Full Text] [Related]
19. Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma.
Gerber NK; Yamada Y; Rimner A; Shi W; Riely GJ; Beal K; Yu HA; Chan TA; Zhang Z; Wu AJ
Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):322-9. PubMed ID: 24679729
[TBL] [Abstract][Full Text] [Related]
20. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations.
Janjigian YY; Park BJ; Zakowski MF; Ladanyi M; Pao W; D'Angelo SP; Kris MG; Shen R; Zheng J; Azzoli CG
J Thorac Oncol; 2011 Mar; 6(3):569-75. PubMed ID: 21150674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
